Control of Osteoclast Activity and Bone Loss by IKK Subunits: New Targets for Therapy
Transcription factor NF-κB has been well recognized as a pivotal player in osteclastogenesis and inflammation-induced bone loss. Here, we discuss our recent results obtained using a genetic approach in mice that indicate the importance of IKKβ, and not IKKα, as a transducer of signals from receptor activator of NF-κB (RANK) to NF-κB. Ablation of IKKβ results in lack of osteoclastogenesis and unresponsiveness of IKKβ-deficient mice to inflammation-induced bone loss. In the need of a more effective therapy for the treatment of inflammatory diseases causing bone resorption, specific inhibition of IKKβ represents a logical alternative strategy to the current therapies.
KeywordsBone Loss Osteoclast Differentiation Bone Erosion Osteoclast Precursor IkappaB Kinase
Unable to display preview. Download preview PDF.
- den Broeder, A., L. van de Putte, et al. 2002. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 29(11): 2288–2298.Google Scholar
- Maini, R., E.W. St. Clair, et al. 1999. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354(9194): 1932–1939.CrossRefPubMedGoogle Scholar
- Rothwarf, D.M., and M. Karin. 1999. The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. Sci STKE 1999(5): RE1.Google Scholar
- Zwerina, J., S. Hayer, et al. 2004. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 50(1): 277–290.CrossRefPubMedGoogle Scholar